IMBdx
Financials
Valuation Metrics
IMBdx's Market Cap is ₩349B. At end of 2025 it was ₩1418B. Ranked #1938 of 2,405 in KR market (top 81%), #1212 of 1,627 on KOSDAQ (top 74%), #206 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 34.90B KRW | KR#1,938/2,405 Sec#206/231 |
| Revenue | 5.60B KRW | KR#2,316/2,405 Sec#190/231 |
| Net Income | -7.59B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 27.12B KRW | KR#2,342/2,405 Sec#224/231 |
| Net Assets | 25.16B KRW | KR#2,214/2,405 Sec#204/231 |
| Employees | 58 | KR#1,974/2,405 Sec#175/231 |
| Value | ||
| P/B | 1.39x | KR#1,771/2,405 Sec#125/231 |
| P/S | 6.23x | KR#2,204/2,405 Sec#150/231 |
| FCF Yield | -20.14% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -30.16% | KR#2,171/2,405 Sec#174/231 |
| ROA | -27.98% | KR#2,289/2,405 Sec#196/231 |
| Op. Margin | -153.75% | KR#2,308/2,405 Sec#182/231 |
| Revenue Growth | 46.12% | KR#233/2,405 Sec#31/231 |
| Financial Health | ||
| Debt Ratio | 7.77% | KR#85/2,405 Sec#18/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | -7.03B KRW | KR#1,586/2,405 Sec#132/231 |
| Cash | 2.08B KRW | KR#2,234/2,405 Sec#214/231 |
| Current Ratio | 21.76x | KR#22/2,405 Sec#10/231 |
| Performance | ||
| 1Y Return | -77.78% | KR#2,332/2,405 Sec#227/231 |
| 1M Return | -16.03% | KR#1,636/2,405 Sec#163/231 |
| From 52W High | -81.20% | KR#2,308/2,405 Sec#213/231 |
| 1Y MDD | -80.17% | KR#2,276/2,405 Sec#201/231 |
| Trading | ||
| Volume | 10,160 shares | KR#1,834/2,405 Sec#180/231 |
| Trading Value | 24.1M KRW | KR#2,030/2,405 Sec#212/231 |
| Foreign Own. | 5.92% | KR#739/2,405 Sec#67/231 |
| Per Share | ||
| EPS | -529 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,756 KRW | KR#2,126/2,405 Sec#178/231 |
Company Info
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.